Immuron Limited ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.01next fiscal year
Monitoring Framework
Key Performance Indicators
Global Product Sales Revenue Annually4.2MTarget: Exceed prior corresponding period levels
Cash Reserves Quarterly10MTarget: Maintain sufficient runway into 2027
ProIBS Australian Market Sales Annually72KTarget: Expand distribution and drive incremental revenue
Watch Items
- IMM-529 Phase 2 Clinical Trial ProgressTrigger: Initiation of Phase 2 clinical trials for recurrent Clostridioides difficile infection (CDI)Action: Monitor patient recruitment rates and clinical safety/efficacy readouts
- Strategic Partnerships for IMM-124E (Travelan) and IMM-529Trigger: Execution of a development or commercialization partnership agreementAction: Evaluate upfront payments, milestone structures, and royalty terms against historical peer deals
- ATM Facility Dilution and Capital AdequacyTrigger: Cash runway dropping below 12 months or further material use of the ATM facilityAction: Assess capital requirements and potential dilution impact on existing shareholders
Research as of 20 Jun 2026